9 completed, 5 recruiting, 3 terminated, 1 active not recruiting. 20 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 9, Recruiting 5, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Focal Segmental Glomerulosclerosis: new trials by email Literature Review of Focal Segmental Glomerulosclerosis trials Research Report on Focal Segmental Glomerulosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) - Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Akebia Therapeutics | 60 | 2025-12-03 | 2026-10-01 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease frexalimab, brivekimig, rilzabrutinib - Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Recruiting | Sanofi | 84 | 2024-12-19 | 2026-10-19 |
| AMPK-activation by Metformin in FSGS: AMP-FSGS Metformin + Standard of Care, Placebo + Standard of Care - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Recruiting | Yale University | 30 | 2023-12-14 | 2026-02-03 |
| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis R3R01 - Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | River 3 Renal Corp. | 43 | 2022-06-15 | 2025-09-29 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease adalimumab - FSGS, MCD | Phase 2 | Completed | University of Michigan | 7 | 2019-10-02 | 2024-10-30 |
| Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Propagermanium, Placebo - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Dimerix Bioscience Pty Ltd | 8 | 2018-11-08 | 2022-07-29 |
| A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome CCX140-B - Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Amgen | 5 | 2018-10-01 | 2025-03-17 |
| Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis Voclosporin - Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Aurinia Pharmaceuticals Inc. | 5 | 2018-06-21 | 2021-09-16 |
| A Study of CCX140-B in Subjects With FSGS Placebo, CCX140-B - FSGS, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Amgen | 46 | 2018-05-17 | 2025-03-13 |
| A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Bardoxolone methyl capsules - IgA Nephropathy, CKD Associated With Type 1 Diabetes | Phase 2 | Completed | Biogen | 103 | 2017-12-26 | 2025-06-03 |
| Valproic Acid for Idiopathic Nephrotic Syndrome Valproic Acid - Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 / Phase 3 | Unknown | Universitair Ziekenhuis Brussel | 15 | 2016-10-01 | 2017-06-20 |
| Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Abatacept, Normal Saline, D5W - Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Bristol-Myers Squibb | 36 | 2016-03-09 | 2021-03-05 |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis RE-021 (Sparsentan), Irbesartan - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Travere Therapeutics, Inc. | 109 | 2014-03-01 | 2025-05-15 |
| Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial Adalimumab, Lisinopril, losartan, and atorvastatin, galactose - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | NYU Langone Health | 32 | 2008-12-01 | 2016-07-11 |
| Permeability Factor in Focal Segmental Glomerulosclerosis Plasma exchange, Cyclophosphamide - Focal Segmental Glomerulosclerosis | Phase 1 / Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 15 | 2000-12-01 | 2016-02-10 |
Glomerulosclerosis, Focal Segmental (20) · Nephrosis, Lipoid (8) · Proteinuria (4) · Glomerulonephritis, IGA (3) · Kidney Diseases (3) · Macular dystrophy, corneal type 1 (3) · Nephritis, Hereditary (3) · Nephrotic Syndrome (3) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranous (1) · IgA Vasculitis (1) · Polycystic Kidney, Autosomal Dominant (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Glomerulonephritis (20) · Male Urogenital Diseases (20) · Nephritis (20) · Urogenital Diseases (20) · Urologic Diseases (20) · Kidney Diseases (17) · Nephrosis (9) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Autoimmune Diseases (4) · Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Immune System Diseases (4)
Adalimumab (2) · CCX140-B (2) · sparsentan (2) · Abatacept (1) · Atorvastatin (1) · Atrasentan (1) · Cyclophosphamide (1) · Galactose (1) · Glucose (1) · Irbesartan (1) · Lisinopril (1) · Losartan (1) · Metformin (1) · N-acetylmannosamine (1) · Plasma Exchange (1)
Amgen (2) · Travere Therapeutics, Inc. (2) · Akebia Therapeutics (1) · Aurinia Pharmaceuticals Inc. (1) · Biogen (1) · Bristol-Myers Squibb (1) · Dimerix Bioscience Pty Ltd (1) · NYU Langone Health (1) · National Human Genome Research Institute (NHGRI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · River 3 Renal Corp. (1) · Sanofi (1) · Tenet Medicines (1)
United States (17) · Italy (5) · United Kingdom (5) · Australia (4) · Canada (3) · France (3) · Germany (3) · Netherlands (3) · Poland (3) · Spain (3) · Belgium (2) · Czechia (2) · Argentina (1) · Brazil (1) · Chile (1)
Cijiang He (1) · Debbie Gipson, MD (1) · Howard Trachtman, M.D. (1) · Howard Trachtman, MD (1) · Jeffrey B Kopp, M.D. (1) · Jennifer Gassman, PhD (1) · Madhav Menon, MD (1) · Peter Janssens, MD (1) · Radko Komers, MD, PhD (1) · Simon Roger, MD (1) · William A Gahl, M.D. (1)
PMID 35224732, PMID 38724717, PMID 40337980, PMID 39899371, PMID 40938675, PMID 19073787, PMID 19932542, PMID 21310077, PMID 26198842, PMID 30361325, PMID 35230699, PMID 36657027, PMID 37254256, PMID 38831932, PMID 39808779, PMID 41442197, PMID 41630898, PMID 42384439
2015 (1), R33DK070341 (1)